These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24444439)

  • 1. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
    Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C
    Eur J Pharmacol; 2014 Feb; 725():18-22. PubMed ID: 24444439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
    Park Y; Jeong YH; Tantry US; Ahn JH; Kwon TJ; Park JR; Hwang SJ; Gho EH; Bliden KP; Kwak CH; Hwang JY; Kim S; Gurbel PA
    Eur Heart J; 2012 Sep; 33(17):2151-62. PubMed ID: 22507978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
    Pelliccia F; Rosano G; Marazzi G; Vitale C; Spoletini I; Franzoni F; Speziale G; Polacco M; Greco C; Gaudio C
    Circ J; 2014; 78(3):679-84. PubMed ID: 24389597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
    Suh JW; Cha MJ; Lee SP; Chae IH; Bae JH; Kwon TG; Bae JW; Cho MC; Rha SW; Kim HS
    J Atheroscler Thromb; 2014; 21(2):140-50. PubMed ID: 24140730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
    Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
    J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
    Satoh M; Tabuchi T; Itoh T; Nakamura M
    Clin Sci (Lond); 2014 Feb; 126(3):233-41. PubMed ID: 23944632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).
    Poyet R; Cuisset T; Frere C; Quilici J; Gaborit B; Moro PJ; Camoin L; Morange PE; Bonnet JL; Alessi MC
    Thromb Res; 2010 Nov; 126(5):e397-9. PubMed ID: 20825983
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
    de Zeeuw D; Anzalone DA; Cain VA; Cressman MD; Heerspink HJ; Molitoris BA; Monyak JT; Parving HH; Remuzzi G; Sowers JR; Vidt DG
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):181-90. PubMed ID: 25660356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study.
    Godino C; Pavon AG; Mangieri A; Salerno A; Cera M; Monello A; Chieffo A; Magni V; Cappelletti A; Margonato A; Colombo A
    Clin Cardiol; 2017 Aug; 40(8):605-611. PubMed ID: 28422300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
    Puccetti L; Santilli F; Pasqui AL; Lattanzio S; Liani R; Ciani F; Ferrante E; Ciabattoni G; Scarpini F; Ghezzi A; Auteri A; Davì G
    Atherosclerosis; 2011 Jan; 214(1):122-8. PubMed ID: 21056418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
    Ovrakh T; Serik S; Kochubiei O
    Georgian Med News; 2017 Apr; (265):7-14. PubMed ID: 28574378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
    Chitose T; Sugiyama S; Sakamoto K; Shimomura H; Yamashita T; Hokamaki J; Tsunoda R; Shiraishi S; Yamashita Y; Ogawa H
    Atherosclerosis; 2014 Nov; 237(1):251-8. PubMed ID: 25262434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
    Soto J; Fernandez de Bobadilla J
    Value Health; 2006; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE; Averna M; Majul C; Muller-Wieland D; De Pellegrin A; Giezek H; Lee R; Lowe RS; Brudi P; Triscari J; Farnier M
    Am J Cardiol; 2013 Dec; 112(12):1885-95. PubMed ID: 24063830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
    Verdoia M; Nardin M; Sartori C; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Atherosclerosis; 2015 Dec; 243(2):389-94. PubMed ID: 26520891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.